Intrasynovial triamcinolone treatment is not associated with incidence of acute laminitis
There is a more recent version of this item available. |
Haseler, Callum J., Jarvis, Gavin E. and McGovern, Kate F. (2020) Intrasynovial triamcinolone treatment is not associated with incidence of acute laminitis. Equine Veterinary Journal. ISSN 0425-1644
Item Type: | Article |
---|
Abstract
Background: Intra-synovial corticosteroid injections are commonly used in the treatment of equine orthopaedic disease, but corticosteroid administration is widely considered a risk factor for the development of laminitis. Despite a list of putative mechanisms and a number of case reports of steroid-induced laminitis, no case-control or cohort studies investigating the association between use of intra-synovial corticosteroids and acute laminitis have been published.
Objectives: To quantify the risk of laminitis posed by intra-synovial triamcinolone acetonide (TA) administration in a mixed population of horses.
Study design: Retrospective observational cohort study.
Methods: Clinical records of horses registered with one large UK equine practice were reviewed retrospectively to identify all horses receiving intra-synovial TA treatment between 1 January 2007 and 31 December 2017. 1,510 horses were selected and records investigated for incidence of laminitis over a 4-month period following treatment. For each TA-treated horse, an untreated horse, individually matched by age, sex, date of treatment and client type, was selected from the clinical records. Untreated horses were then investigated for laminitis over the same 4-month period. Data was analysed in a 2×2 contingency table using Fisher’s exact test.
Results: 489 horses were lost to follow-up and 55 horses were excluded, leaving 966 treated and matched, untreated horses. The incidence of laminitis over the 4-month study period in both groups was identical: 3/966 horses (0.31%) (95% C.I. [0.08%, 0.91%]), equivalent to 0.93 cases per 100 horses per year (P >0.9).
Main limitations: Retrospective study; large proportion (489/1510) of horses lost to follow-up; large proportion of study population were racehorses; selection method resulted in disproportionate selection of horses born before 2013; similar incidence between groups may reflect existing risk-based selection by clinicians.
Conclusions: Intra-synovial triamcinolone acetonide administration does not increase the risk of laminitis in this study population.
|
PDF
Haseler (manuscript) Intra-synovial triamcinolone treatment, EVJ.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (509kB) | Preview |
More Information
Depositing User: Gavin Jarvis |
Identifiers
Item ID: 12892 |
Identification Number: https://doi.org/10.1111/evj.13361 |
ISSN: 0425-1644 |
URI: http://sure.sunderland.ac.uk/id/eprint/12892 | Official URL: http://dx.doi.org/10.1111/evj.13361 |
Users with ORCIDS
Catalogue record
Date Deposited: 04 Jan 2021 11:38 |
Last Modified: 20 Nov 2021 03:38 |
Author: | Gavin E. Jarvis |
Author: | Callum J. Haseler |
Author: | Kate F. McGovern |
University Divisions
Faculty of Health Sciences and Wellbeing > School of MedicineSubjects
Sciences > Biomedical SciencesSciences > Pharmacy and Pharmacology
Actions (login required)
View Item (Repository Staff Only) |
Available Versions of this Item
- Intrasynovial triamcinolone treatment is not associated with incidence of acute laminitis. (deposited 04 Jan 2021 11:38) [Currently Displayed]